Evidence map›Paper›PMID 42866370›Full record

ReviewFrontiers in immunology2026

Remodeling of the brain immune microenvironment in Alzheimer's disease: interactions among microglia, astrocytes, complement, and the neurovascular unit.

Tong Wang, Lu Wang, Jianing Cao, Yi Zhao, Zongling He, Fengmei Lu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tong WangThe Clinical Hospital of Chengdu Brain Science Institute, MOE (Ministry of Education) Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.
Lu WangThe Clinical Hospital of Chengdu Brain Science Institute, MOE (Ministry of Education) Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.
Jianing CaoThe Clinical Hospital of Chengdu Brain Science Institute, MOE (Ministry of Education) Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.
Yi ZhaoThe Clinical Hospital of Chengdu Brain Science Institute, MOE (Ministry of Education) Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.
Zongling HeThe Clinical Hospital of Chengdu Brain Science Institute, MOE (Ministry of Education) Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.
Fengmei LuThe Clinical Hospital of Chengdu Brain Science Institute, MOE (Ministry of Education) Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease is defined by amyloid-β deposition and tau pathology, yet comparable pathological burdens do not necessarily correspond to similar cognitive trajectories, regional patterns of injury, or treatment responses. This discordance suggests that the cellular and tissue microenvironment may materially shape disease progression. Genetic studies, single-cell and spatial omics, and human-derived models further indicate that microglia, astrocytes, the complement system, and the neurovascular unit undergo coordinated remodeling during the preclinical phase of AD and influence pathological spread, synaptic injury, and neurodegeneration through intercellular interactions. Remodeling of the brain immune microenvironment is regionally specific, stage dependent, and heterogeneous across cellular states; conventional pro-inflammatory/anti-inflammatory or activated/resting dichotomies therefore fail to capture its dynamics. This review examines the remodeling of the AD brain immune microenvironment through interactions among microglia, astrocytes, complement, and the neurovascular unit, with emphasis on their roles in Aβ and tau pathology, synaptic injury, lipid homeostasis, and vascular dysfunction, and considers the interpretive limits of single-cell and spatial-omics evidence. Current evidence supports a dynamically reconfigured system rather than a uniformly escalating inflammatory response. Therapeutic strategies should move beyond broad anti-inflammatory approaches to preserve effective pathological clearance within appropriate disease windows, limit maladaptive synaptic injury, and restore glial and neurovascular homeostasis.

Indexed as

Alzheimer DiseaseAstrocytesBrainCellular MicroenvironmentComplement System ProteinsMicrogliaAmyloid beta-PeptidesAnimalsHumansAmyloid beta-PeptidesComplement System ProteinsAlzheimer’s diseaseastrocytescomplement systemmicrogliaprecision stratification

Identifiers

PMID42866370
PMCPMC13656213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.